[go: up one dir, main page]

MA57000B1 - Dérivés d'alpha-d-galactopyranoside - Google Patents

Dérivés d'alpha-d-galactopyranoside

Info

Publication number
MA57000B1
MA57000B1 MA57000A MA57000A MA57000B1 MA 57000 B1 MA57000 B1 MA 57000B1 MA 57000 A MA57000 A MA 57000A MA 57000 A MA57000 A MA 57000A MA 57000 B1 MA57000 B1 MA 57000B1
Authority
MA
Morocco
Prior art keywords
diyl
alpha
compounds
formula
galactopyranoside
Prior art date
Application number
MA57000A
Other languages
English (en)
Inventor
Martin Bolli
Cornelia Zumbrunn
John Gatfield
Corinna Grisostomi
Lubos Remen
Christoph Sager
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA57000B1 publication Critical patent/MA57000B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés de formule (i) dans laquelle ar1, r1 et r2 sont tels que décrits dans la description, et a est du 4,5-dihydroisoxazol-3,5-diyle, de l'imidazolidin-4-one-1,3-diyle, de l'oxazol-2-one-3,5-diyle et de l'oxazolidine-2-one-3,5-diyle, du 1, 2,3-triazole-1,4-diyle, de l'isoxazole-3,5-diyle, de l'imidazole-1,4-diyle, et de l'isothiazole-3,5-diyle ; et leur préparation, leurs sels pharmaceutiquement acceptables, et leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant un ou plusieurs composés de formule (i), et en particulier leur utilisation en tant qu'inhibiteurs de galectine 3.
MA57000A 2019-08-29 2020-08-28 Dérivés d'alpha-d-galactopyranoside MA57000B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019073063 2019-08-29
PCT/EP2020/074121 WO2021038068A1 (fr) 2019-08-29 2020-08-28 Dérivés d'alpha-d-galactopyranoside

Publications (1)

Publication Number Publication Date
MA57000B1 true MA57000B1 (fr) 2024-03-29

Family

ID=72561746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57000A MA57000B1 (fr) 2019-08-29 2020-08-28 Dérivés d'alpha-d-galactopyranoside

Country Status (22)

Country Link
US (2) US12319672B2 (fr)
EP (1) EP4021904B1 (fr)
JP (1) JP7612669B2 (fr)
KR (1) KR102824799B1 (fr)
CN (1) CN114585619B (fr)
AU (1) AU2020338816B2 (fr)
BR (1) BR112022003562A2 (fr)
CA (1) CA3148365A1 (fr)
ES (1) ES2972551T3 (fr)
HR (1) HRP20240297T1 (fr)
HU (1) HUE066221T2 (fr)
IL (1) IL290815B2 (fr)
MA (1) MA57000B1 (fr)
MX (1) MX2022002339A (fr)
MY (1) MY207787A (fr)
PH (1) PH12022550436A1 (fr)
PL (1) PL4021904T3 (fr)
RS (1) RS65294B1 (fr)
SA (1) SA522431777B1 (fr)
TW (1) TWI864085B (fr)
UA (1) UA129205C2 (fr)
WO (1) WO2021038068A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010076B1 (fr) 2019-08-09 2024-01-17 Idorsia Pharmaceuticals Ltd Dérivés (hétéro)aryl-méthyl-thio-bêta-d-galactopyranoside
US12410208B2 (en) 2019-08-09 2025-09-09 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
HUE070924T2 (hu) 2019-08-15 2025-07-28 Idorsia Pharmaceuticals Ltd 2-Hidroxicikloalkán-1-karbamoil-származékok
IL301815A (en) 2020-10-06 2023-06-01 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
AU2021370994A1 (en) 2020-11-02 2023-06-29 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
ES3032987T3 (en) 2021-02-09 2025-07-29 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
CN116888113A (zh) 2021-03-03 2023-10-13 爱杜西亚药品有限公司 经三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
IN2015DN02573A (fr) 2012-10-31 2015-09-11 Galecto Biotech Ab
CN104955471A (zh) 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
EP3828191A3 (fr) * 2015-01-30 2021-08-18 Galecto Biotech AB Nouvel inhibiteur de galactoside de galectines
EP3456717B1 (fr) 2015-07-06 2021-03-17 Gilead Sciences, Inc. Dérivé de 4,6-diamino-quinoline-3-carbonitrile en tant que modulateur de cancer osaka thyroid (cot) pour le traitement de maladie inflammatoire
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
WO2018209255A1 (fr) 2017-05-12 2018-11-15 Galectin Sciences, Llc Composés pour la prévention et le traitement de maladies et leur utilisation
WO2018209276A1 (fr) 2017-05-12 2018-11-15 Galectin Sciences, Llc Composés pour le traitement de troubles de la résistance systémique à l'insuline et leur utilisation
WO2019067702A1 (fr) * 2017-09-27 2019-04-04 Bristol-Myers Squibb Company Inhibiteurs à petites molécules de galectine-3
WO2019075045A1 (fr) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company Inhibiteurs à petites molécules de galectine-3
AU2018361991A1 (en) 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
US12497428B2 (en) 2018-10-15 2025-12-16 Galecto Biotech Ab Galactoside inhibitor of galectins
CA3114055A1 (fr) 2018-10-15 2020-04-23 Galecto Biotech Ab Promedicament de galactoside inhibiteur de galectines
CA3116515A1 (fr) 2018-11-21 2020-05-28 Galecto Biotech Ab Inhibiteurs alpha-d-galactoside de galectines
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CA3141436A1 (fr) 2019-07-03 2021-01-07 Fredrik Zetterberg Nouveau galactoside comme inhibiteur de galectines
CN114450282A (zh) 2019-07-05 2022-05-06 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
US12410208B2 (en) 2019-08-09 2025-09-09 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
EP4010076B1 (fr) 2019-08-09 2024-01-17 Idorsia Pharmaceuticals Ltd Dérivés (hétéro)aryl-méthyl-thio-bêta-d-galactopyranoside
HUE070924T2 (hu) 2019-08-15 2025-07-28 Idorsia Pharmaceuticals Ltd 2-Hidroxicikloalkán-1-karbamoil-származékok
IL301815A (en) 2020-10-06 2023-06-01 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
AU2021370994A1 (en) 2020-11-02 2023-06-29 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
ES3032987T3 (en) 2021-02-09 2025-07-29 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
CN116888113A (zh) 2021-03-03 2023-10-13 爱杜西亚药品有限公司 经三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物

Also Published As

Publication number Publication date
RS65294B1 (sr) 2024-04-30
IL290815B1 (en) 2025-04-01
WO2021038068A1 (fr) 2021-03-04
CN114585619B (zh) 2024-09-27
HUE066221T2 (hu) 2024-07-28
EP4021904A1 (fr) 2022-07-06
KR20220053622A (ko) 2022-04-29
BR112022003562A2 (pt) 2022-05-24
CA3148365A1 (fr) 2021-03-04
US20250257056A1 (en) 2025-08-14
JP7612669B2 (ja) 2025-01-14
TWI864085B (zh) 2024-12-01
HRP20240297T1 (hr) 2024-05-10
IL290815B2 (en) 2025-08-01
EP4021904B1 (fr) 2024-01-03
TW202122092A (zh) 2021-06-16
AU2020338816B2 (en) 2026-01-08
US20220281855A1 (en) 2022-09-08
MY207787A (en) 2025-03-19
AU2020338816A1 (en) 2022-04-14
EP4021904C0 (fr) 2024-01-03
MX2022002339A (es) 2022-04-06
JP2022546029A (ja) 2022-11-02
UA129205C2 (uk) 2025-02-05
IL290815A (en) 2022-04-01
ES2972551T3 (es) 2024-06-13
KR102824799B1 (ko) 2025-06-24
CN114585619A (zh) 2022-06-03
US12319672B2 (en) 2025-06-03
SA522431777B1 (ar) 2024-04-30
PH12022550436A1 (en) 2022-12-19
PL4021904T3 (pl) 2024-05-13

Similar Documents

Publication Publication Date Title
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
TN2009000450A1 (fr) Derives de pyridine
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA27796A1 (fr) Composes n-heterocycliques condenses et leur utilisation comme antagonistes des recepteurs de crf
MA26857A1 (fr) Azaindoles
MA49127B1 (fr) Dérivés d'indole n-substitués
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA63589B1 (fr) Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA31873B1 (fr) Inhibiteurs de la peptide déformylase